FDA Inspection 1227134 — Breckenridge Pharmaceutical, Inc
The FDA completed an inspection of Breckenridge Pharmaceutical, Inc on Jan 5, 2024 in Berlin, CT. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Jan 5, 2024
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Berlin, CT (United States)
Additional Details
Postmarket Adverse Drug Experience (PADE)